SCHEMBL13765709

SCHEMBL13765709

Cc1nc(CC(=O)O)c(C)o1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.57
GABRR1 P24046 1/20 0.40
AGBL2 Q5U5Z8 2/20 0.37
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HPGD P15428 1/20 0.36
HSD17B10 Q99714 2/20 0.35
APEX1 P27695 1/20 0.33
CYP1A2 P05177 1/20 0.33
PPARG P37231 3/20 0.33
PPARA Q07869 3/20 0.33
RAB9A P51151 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GAA P10253 1/20 0.32
NR4A1 P22736 1/20 0.32
NR4A2 P43354 1/20 0.32
NR4A3 Q92570 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2024191 0.83 KDM4E (0.46) KDM4EGABRR1SMN1; SMN2HPGDPPARG
SCHEMBL13799704 0.83 KDM4E (0.41) KDM4E
SCHEMBL3309078 0.82 HTT (0.41) KDM4ERAB9AALDH1A1POLBL3MBTL1
SCHEMBL13765710 0.79 GAA (0.39) KDM4EMAPTSMN1; SMN2HSD17B10RAB9A
SCHEMBL4675656 0.77 KDM4E (0.51) KDM4EGABRR1AGBL2MAPTSMN1; SMN2
SCHEMBL5558215 0.77 KDM4E (0.51) KDM4EGABRR1AGBL2MAPTSMN1; SMN2
SCHEMBL17859504 0.76 FBP1 (0.44) KDM4EGABRR1AGBL2MAPTSMN1; SMN2
SCHEMBL15637053 0.74 KDM4E (0.49) KDM4EGABRR1AGBL2MAPTSMN1; SMN2
SCHEMBL15639468 0.74 KDM4E (0.39) KDM4EGABRR1AGBL2MAPTSMN1; SMN2
SCHEMBL893027 0.73 KDM4E (1.00) KDM4EHPGDPPARGPPARARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9700543-B2 GLP-1 receptor stabilizers and modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-07-11 US disclosed
EP-2713722-B1 NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS RECEPTOS LLC (US) 2017-03-15 EP disclosed
US-20160310471-A1 NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS RECEPTOS LLC 2016-10-27 US disclosed
US-9278910-B2 GLP-1 receptor stabilizers and modulators RECEPTOS, INC. (US) 2016-03-08 US disclosed
US-20140336185-A1 NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS RECEPTOS LLC 2014-11-13 US disclosed
WO-2012166951-A9 NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS RECEPTOS, INC. (US) 2013-02-21 WO disclosed
WO-2012166951-A1 NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS RECEPTOS, INC. (US) 2012-12-06 WO disclosed
US-7560548-B2 Morpholin-acetamide derivatives for the treatment of inflammatory diseases GLAXO GROUP LIMITED (GB) 2009-07-14 US disclosed
US-20090163495-A1 MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LIMITED (GB) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336185-A1 NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS GLP1R, GIPR, GHSR KDM4E 3905/4885GABRR1 1006/4885AGBL2 2790/4885
US-20160310471-A1 NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS GLP1R, GIPR, GHSR KDM4E 3905/4885GABRR1 1006/4885AGBL2 2790/4885
US-20090163495-A1 MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES ARG1, ARG2, NFKBIA KDM4E 3869/4885GABRR1 1279/4885AGBL2 2761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.